NIPPON CHEMIPHAR CO., LTD.
4539 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 千代田区岩本町二丁目２番３号
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
NIPPON CHEMIPHAR CO., LTD. is a leading Japanese pharmaceutical company focused on enhancing global health through innovative drug development. The company operates in three primary business areas: creating high-quality generic drugs, pioneering innovative products rooted in allergy research, and developing groundbreaking new therapies based on proprietary technologies, including alkalization therapy. Committed to expanding its international presence, Chemiphar aims to address health challenges and improve societal well-being by delivering effective pharmaceutical solutions and health-related services. With a strong emphasis on quality and innovation, NIPPON CHEMIPHAR strives to make a meaningful difference in the lives of individuals worldwide.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-20 03:58 |
Inside Information Statement
臨時報告書
|
Japanese | 30.9 KB | |
| 2025-06-20 03:57 |
Internal Control over Financial Reporting
内部統制報告書－第93期(2024/04/01－2025/03/31)
|
Japanese | 23.8 KB | |
| 2025-06-20 03:57 |
Regulatory News Service
確認書
|
Japanese | 8.6 KB | |
| 2025-06-20 03:56 |
Annual Report
有価証券報告書－第93期(2024/04/01－2025/03/31)
|
Japanese | 1.2 MB | |
| 2024-11-13 01:21 |
Interim Report
半期報告書－第93期(2024/04/01－2025/03/31)
|
Japanese | 223.1 KB | |
| 2024-11-13 01:21 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-06-24 08:03 |
Inside Information Statement
臨時報告書
|
Japanese | 18.7 KB | |
| 2024-06-24 03:28 |
Inside Information Statement
臨時報告書
|
Japanese | 25.6 KB | |
| 2024-06-24 03:27 |
Regulatory News Service
確認書
|
Japanese | 8.6 KB | |
| 2024-06-24 03:26 |
Internal Control over Financial Reporting
内部統制報告書－第92期(2023/04/01－2024/03/31)
|
Japanese | 23.2 KB | |
| 2024-06-24 03:24 |
Annual Report
有価証券報告書－第92期(2023/04/01－2024/03/31)
|
Japanese | 1.2 MB | |
| 2024-02-13 04:31 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-02-13 04:30 |
Quarterly Report
四半期報告書－第92期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 230.5 KB | |
| 2023-11-15 02:46 |
Major Shareholding Notification
大量保有報告書
|
Japanese | 38.2 KB | |
| 2023-11-13 01:07 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
D.Western Therapeutics Institute, Inc. | Japan | 4576 | |
|
EARNZ PLC | United Kingdom | EARN | |
|
Eevia Health Plc | Finland | EEVIA | |
|
Egetis Therapeutics | Sweden | EGTX | |
|
EIKEN CHEMICAL CO.,LTD. | Japan | 4549 | |
|
Eisai Co., Ltd. | Japan | 4523 | |
|
ELARIS AG | Germany | ELS | |
|
Enervit | Italy | ENV | |
|
Enorama Pharma AB | Sweden | ERMA | |
|
Enzymatica AB | Sweden | ENZY |